Thrombosis and thrombolysis: platelet membrane glycoproteins
Related Experiment Video
Updated: Jul 15, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
1Suite 1, Westmead Private Hospital, Westmead, NSW 2145, Australia. wpcmps@bigpond.net.au
Insights
Therapies for acute coronary syndromes have advanced, focusing on dissolving or mechanically removing coronary thrombosis caused by atherosclerotic plaque rupture. Anti-platelet therapies are crucial for managing this cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Thrombosis Research
- Atherosclerosis Studies
Background:
- Acute coronary syndromes are primarily caused by coronary thrombosis.
- Coronary thrombosis is precipitated by atherosclerotic plaque rupture.
- Platelet-rich thrombus formation is a key feature.
Purpose of the Study:
- To review the evolution of acute coronary syndrome therapies.
- To highlight the role of thrombolytic agents and percutaneous coronary interventions.
- To discuss the significance of anti-platelet therapy and future research directions.
Main Methods:
- Review of advancements in acute coronary syndrome treatment over 25 years.
- Examination of the role of thrombolytic agents and percutaneous coronary interventions (angioplasty and stenting).
- Discussion of platelet membrane glycoproteins and their role in therapies.
Main Results:
- Therapies have evolved to routinely address coronary thrombosis.
- Percutaneous coronary interventions and thrombolytic agents are standard treatments.
- Anti-platelet therapy is established for cardiovascular disease management.
Conclusions:
- Coronary thrombosis due to plaque rupture is central to acute coronary syndromes.
- Targeting platelet function has led to specific therapies.
- Future research should focus on markers for plaque instability.
Abstract:
Over the last quarter of a century, therapy for acute coronary syndromes has rapidly evolved. The major causative factor for acute coronary syndromes, particularly acute myocardial infarction, is now recognised to be coronary thrombosis and therapies using thrombolytic agents to dissolve thrombus or percutaneous coronary interventions (angioplasty and stenting) to mechanically disrupt thrombus and restore vessel patency are now routine. The precipitant for coronary thrombus is believed to be atherosclerotic plaque rupture. Plaque rupture has been demonstrated at autopsy in humans and in vivo in an experimental animal model for atherosclerosis. Thrombus formed at these sites is platelet rich and anti-platelet therapy has an established role in the treatment of cardiovascular disease. The study of platelet membrane glycoproteins, which mediate platelet adhesion and aggregation, has resulted in specific therapies. Future directions for research with clinical relevance include the development of markers for plaque instability.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
08:50Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Venous Thrombosis I: Introduction